Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Sorafenib, the first oral anti-angiogenic multikinase inhibitor, is primarily used in the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma, and thyroid cancer. Common toxicities experienced by patients treated with sorafenib limit its use and affect adherence to treatment, reducing sorafenib efficacy. No biomarkers are currently available to identify patients at risk of toxicity.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
